| pubmed-article:14702922 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14702922 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:14702922 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:14702922 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:14702922 | pubmed:issue | 46 | lld:pubmed |
| pubmed-article:14702922 | pubmed:dateCreated | 2004-1-1 | lld:pubmed |
| pubmed-article:14702922 | pubmed:abstractText | Positron emission tomography (PET) is a useful tool for the investigation of certain physiological changes and for the evaluation of the distribution, and receptor binding of drugs labelled with positron emitting isotopes. Vinpocetine (ethyl-apovincaminate) is a neuroprotective drug widely used in the prevention and treatment of cerebrovascular diseases. In the clinical practice vinpocetine is usually administered to the patients in intravenous infusion followed by long-term oral treatment. Until presently human data describing vinpocetine's kinetics and brain distribution came from ex vivo (blood, plasma, liquor) and post mortem (brain autoradiography) measurements. | lld:pubmed |
| pubmed-article:14702922 | pubmed:language | hun | lld:pubmed |
| pubmed-article:14702922 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14702922 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14702922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14702922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14702922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14702922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14702922 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14702922 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:14702922 | pubmed:issn | 0030-6002 | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:HalldinChrist... | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:FardeLarsL | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:SandellJohanJ | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:GulyásBalázsB | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:BURTJ HJH | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:SóvágóJuditJ | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:CselényiZsolt... | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:KissBélaB | lld:pubmed |
| pubmed-article:14702922 | pubmed:author | pubmed-author:KárpátiEgonE | lld:pubmed |
| pubmed-article:14702922 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14702922 | pubmed:day | 16 | lld:pubmed |
| pubmed-article:14702922 | pubmed:volume | 144 | lld:pubmed |
| pubmed-article:14702922 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14702922 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14702922 | pubmed:pagination | 2271-6 | lld:pubmed |
| pubmed-article:14702922 | pubmed:dateRevised | 2009-10-21 | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:meshHeading | pubmed-meshheading:14702922... | lld:pubmed |
| pubmed-article:14702922 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14702922 | pubmed:articleTitle | [Human positron emission tomography with oral 11C-vinpocetine]. | lld:pubmed |
| pubmed-article:14702922 | pubmed:affiliation | Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institute, Stockholm. | lld:pubmed |
| pubmed-article:14702922 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14702922 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14702922 | pubmed:publicationType | English Abstract | lld:pubmed |
